Joltoo
Investors
Grant catalog
Browse catalogFind your matchesFundersPrograms
FundraisingInsights
DeepTech 2026 PlaybookRequest access
Browse all
  1. Home
  2. /Investors
  3. /Synthetic Biology
  4. /Newpath Partners
Newpath Partners

Newpath Partners

Pure DeepTechBoston, United StatesActiveWebsiteLinkedIn
Stage FocusSeed, Series A
GeographyUS
TypeVC
Last Activity2025
Industry Focus
Industries
Synthetic BiologyBiotechMedtech
Technical BenchStrong
Investor TypeDeepTech Purist
ExposureMostly DeepTech Investments
Bio

Newpath Partners was founded in 2018 by Tom Cahill, an MD/PhD physician-scientist who moved into investing. Fund II closed at $350M in December 2021 with a mandate to create life sciences companies, not just fund them.

The firm specializes in breakthrough biology platforms — gene editing and regenerative medicine in particular. The portfolio includes 13 companies, with 2 IPOs and 3 acquisitions (...

Notable Investments
P
Prime Medicine
C
Chroma Medicine
M
Myeloid Therapeutics
K
Kojin Therapeutics
E
Exo Therapeutics

Similar Funds

Illumina Ventures

Illumina Ventures

San Diego, United States

Pure DeepTechSynthetic BiologyBiotechMedtechSeedSeries A
The Production Board

The Production Board

San Francisco, United States

Pure DeepTechSynthetic BiologyAgritechBiotechPre-SeedSeed
a16z Bio + Crypto (Andreessen Horowitz)

a16z Bio + Crypto (Andreessen Horowitz)

Menlo Park, United States

GeneralistSynthetic BiologyBlockchainBiotechSeedSeries A
SOSV

SOSV

New York, United States

Pure DeepTechSynthetic BiologyClimate TechRoboticsPre-SeedSeed
GRIDX

GRIDX

Buenos Aires, Argentina

DeepTech NativeSynthetic BiologyBiotechAgritechPre-SeedSeed
KdT Ventures

KdT Ventures

United States

Pure DeepTechSynthetic BiologyBiotechClimate TechPre-SeedSeed
Joltoo
SecurityPrivacy PolicyTerms of Service
© 2026 Joltoo. All rights reserved.